180 Life Sciences’ Woody Sets Out Vision For Repurposing Anti-TNF Biologics
CEO Expands On Recent Announcement Of Collaboration With Celltrion
After 180 Life Sciences recently struck a deal with Korea’s Celltrion to support its work in repurposing off-patent biologics, CEO Jim Woody speaks to Generics Bulletin about what the collaboration means for the company and its next steps.
You may also be interested in...
180 Life Sciences has found that adalimumab can effectively treat nodule hardness and size in Dupuytren’s disease during a Phase IIb study. But, the company’s CEO Jim Woody tells Generics Bulletin, regulators in the UK and US have requested more information before they will press on with authorization.
Adalimumab could find itself with a tenth official indication, after 180 Life Sciences found that it was able to effectively treat nodule hardness and size in Dupuytren’s disease during a phase IIb study.
As 2021 drew to a close, there was no shortage of exciting developments for the off-patent industry. Alongside news of a strategic review affecting one of the biggest generics and biosimilars players, Generics Bulletin also held its annual Global Generics & Biosimilars Awards and brought readers fresh and exclusive insights from top industry executives.